ATE517629T1 - Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems - Google Patents

Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems

Info

Publication number
ATE517629T1
ATE517629T1 AT02774915T AT02774915T ATE517629T1 AT E517629 T1 ATE517629 T1 AT E517629T1 AT 02774915 T AT02774915 T AT 02774915T AT 02774915 T AT02774915 T AT 02774915T AT E517629 T1 ATE517629 T1 AT E517629T1
Authority
AT
Austria
Prior art keywords
protein
immune system
crmp
sequence
system diseases
Prior art date
Application number
AT02774915T
Other languages
English (en)
Inventor
Pascale Giraudon
Marie-Francoise Belin
Christophe Malcus
Pierre Colas
Jean-Christophe Antoine
Jerome Honnorat
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0111627A external-priority patent/FR2829392B1/fr
Priority claimed from FR0113342A external-priority patent/FR2830762B1/fr
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE517629T1 publication Critical patent/ATE517629T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02774915T 2001-09-07 2002-09-09 Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems ATE517629T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0111627A FR2829392B1 (fr) 2001-09-07 2001-09-07 Utilisation de crmps pour la fabrication d'un medicament destine a traiter les maladies liees a un dysfonctionnement du systeme immunitaire
FR0113342A FR2830762B1 (fr) 2001-10-16 2001-10-16 Utilisation d'une proteine de la famille des crmps pour le traitement des maladies liees au systeme immunitaire
PCT/FR2002/003056 WO2003022298A2 (fr) 2001-09-07 2002-09-09 Utilisation d'une proteine de la famille des crmps pour le traitement des maladies liees au systeme immunitaire

Publications (1)

Publication Number Publication Date
ATE517629T1 true ATE517629T1 (de) 2011-08-15

Family

ID=26213178

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02774915T ATE517629T1 (de) 2001-09-07 2002-09-09 Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems

Country Status (7)

Country Link
US (1) US7820375B2 (de)
EP (1) EP1435993B1 (de)
JP (1) JP4499414B2 (de)
AT (1) ATE517629T1 (de)
AU (1) AU2002341090A1 (de)
CA (1) CA2461692A1 (de)
WO (1) WO2003022298A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2853909A1 (fr) * 2003-04-16 2004-10-22 Galderma Res & Dev Genes du psoriasis
EP2002005A4 (de) * 2006-03-17 2009-12-09 Univ Mcgill Identifizierung von crmp4 als konvergenzregulator der axonauswuchshemmung
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
DE102007022669A1 (de) * 2007-05-11 2008-11-20 Carsten Dr. Korth Verwendung von CRMP1 als Marker für chronisch psychiatrische Erkrankungen
DE102007022670A1 (de) * 2007-05-11 2008-11-13 Carsten Dr. Korth Verwendung von CRMP1 als Target für chronisch psychiatrische Erkrankungen
US20120135009A1 (en) * 2009-07-16 2012-05-31 Pascale Giraudon Cleaved and Phosphorylated CRMP2 as Blood Marker of Inflammatory Diseases of the Central Nervous System
EP2478088B1 (de) * 2009-09-16 2016-08-31 Life Technologies Corporation Lysepuffer zur extraction von nukleinsäuren
WO2014139539A1 (en) * 2013-03-15 2014-09-18 Syddansk Universitet Inhibitor of dpysl3/crmp4 for treatment of bone loss
MX393605B (es) * 2015-06-26 2025-03-24 Univ California Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo
CN113238045B (zh) * 2021-04-27 2021-12-28 南方医科大学南方医院 Crmp2及抗crmp2抗体的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758337B1 (fr) * 1997-01-14 1999-03-05 Commissariat Energie Atomique Methode de criblage de substances a action therapeutique dans le traitement des esst comprenant une etape d'isolement de la prpres, a partir de la rate, procede d'isolement de le prpres et ses applications
FR2759701B1 (fr) 1997-02-19 1999-06-04 Inst Nat Sante Rech Med Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
FR2805540B1 (fr) 2000-02-29 2004-04-09 Inst Nat Sante Rech Med Nouvelle proteine ulip humaine et son utilisation dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
US20020119944A1 (en) * 2000-11-09 2002-08-29 Michelle Aguera Use of Ulip-and/or Ulip2 in the treatment of myelin disorders
ZA200204907B (en) * 2001-06-26 2003-03-03 Univ Nat Taiwan Collapsin Response Mediator Protein-1.

Also Published As

Publication number Publication date
US7820375B2 (en) 2010-10-26
JP4499414B2 (ja) 2010-07-07
US20050106143A1 (en) 2005-05-19
JP2005508315A (ja) 2005-03-31
AU2002341090A1 (en) 2003-03-24
WO2003022298A3 (fr) 2004-05-06
EP1435993A2 (de) 2004-07-14
WO2003022298A2 (fr) 2003-03-20
CA2461692A1 (fr) 2003-03-20
EP1435993B1 (de) 2011-07-27

Similar Documents

Publication Publication Date Title
RU2432364C2 (ru) ПОЛИКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ Nogo, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ АНТИТЕЛА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
DE60129799D1 (de) Verfahren zur steigerung des haarwuchses durch wnt polypeptid
HUP0202532A2 (hu) Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása
EA201070623A1 (ru) Конструкция из полипептидов однодоменных антител, применение композиции, ее содержащей, и способ лечения ревматоидного артрита
ATE548388T1 (de) An den interleukin-4-rezeptor bindende antikörper
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
DE60223058D1 (de) Zusammensetzungen und verfahren zur behandlung von diabetes
CN101985036A (zh) 淀粉样β(1-42)蛋白寡聚体、其衍生物及抗体、其制备方法和用途
EP1361229A3 (de) Verwendung von Tyrosine Kinase (PYK2) zur Produktion von Antikörper
MXPA04001547A (es) Proteina de leptina porcina, antisentido y anticuerpo.
ATE380867T1 (de) Lactoferrinrezeptorgen von moraxella
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
ATE545658T1 (de) Verfahren zur behandlung von synovialsarkom
AU2002341090A1 (en) Use of a protein of the crmp family for treating diseases related to the immune system
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
Nishifuji et al. Cloning of swine desmoglein 1 and its direct proteolysis by Staphylococcus hyicus exfoliative toxins isolated from pigs with exudative epidermitis
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
ATE336501T1 (de) Chi-conotoxinpeptide als inhibitoren neuronaler amintransporter
EP1734827A4 (de) Verfahren und zusammensetzungen zur behandlung von mit anomaler mikrosatellitenexpansion in verbindung stehenden krankheiten
NO962596L (no) Nytt tumorsupressorgen
DE50015355D1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties